Quantcast
Last updated on April 17, 2014 at 10:49 EDT

Latest Darbepoetin alfa Stories

2008-11-07 12:00:23

Affymax, a biopharmaceutical company, has announced positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients. In the Phase II study, 182 patients using Hematide once every four weeks for up to 23 months successfully maintained average hemoglobin levels within an 11 to 12g/dl target range. A retrospective analysis of 115 patients from a Phase II...

2008-11-06 11:17:54

Affymax, Inc. (Nasdaq: AFFY) today announced at the American Society of Nephrology Renal Week 2008 in Philadelphia positive results from a long-term safety and effectiveness study of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. In the Phase 2 study analysis presented by Iain Macdougall, M.D., Hematide clinical investigator and honorary senior lecturer at King's College Hospital in London, 182 patients...

2008-11-03 06:00:21

Medgenics (AIM:MEDG), is pleased to announce encouraging preliminary data for its Phase I/II clinical trial. The landmark Phase I/II clinical trial of Medgenics' EPODURE Biopump, for providing sustained treatment of anemia in subjects with chronic kidney disease, is underway. The current trial is designed to assess the safety and efficacy of the EPODURE Biopump in providing sustained elevation of hemoglobin by delivering sufficient supplemental amounts of the protein erythropoietin (EPO)...

2008-09-29 12:00:40

The U.S. Food and Drug Administration issued an advisory about preliminary results of a German study involving the drug known as Procrit, Eprex or Epogen. The federal agency said the German study is investigating whether the anti-anemia drug epoetin alfa, marketed as Eprex in Germany, can improve the neurological functioning of stroke victims. The FDA said three months after the start of the study, 16 percent of the patients who had received the drug had died, compared with 9 percent of...

2008-07-11 18:00:35

Amgen (NASDAQ:AMGN) today announced that it has reached an agreement to settle its outstanding antitrust litigation with Ortho Biotech Products L.P. (Ortho Biotech). Ortho Biotech, a subsidiary of Johnson & Johnson (NYSE: JNJ), had alleged that discounts offered to oncology clinics on Amgen's Neupogen and Neulasta and Aranesp products violated antitrust laws. Under terms of the agreement, Amgen will pay Ortho Biotech $200 million and the pending litigation in New Jersey District...

2008-07-10 12:01:17

Affymax has completed enrollment in the first of four Phase III clinical trials of its lead investigational therapy, Hematide, which is being evaluated for the treatment of anemia in chronic renal failure patients. Pearl 1 is fully enrolled with over 475 non-dialysis patients from over 70 sites in the US. The Hematide Phase III program, involving a total of approximately 2,400 chronic renal failure patients, consists of four open-label, randomized controlled clinical trials in the US and...

2008-07-09 09:01:01

Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the first of four Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 1 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 475 non-dialysis patients from over 70 sites in the United States. "We are delighted that the rate of enrollment...

2008-06-30 09:03:37

Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has begun in a Phase 2 clinical trial of Hematide(TM) to correct anemia in patients with chronic renal failure (CRF) who are undergoing dialysis and are not actively being treated with an erythropoiesis stimulating agent (ESA). The trial is intended to generate data for Hematide as an anemia correction therapy in this segment of the CRF patient population, some of whom may be ESA-naive. This is the first Hematide correction study in...

2008-05-06 09:01:23

EXTON, Pa., May 6 /PRNewswire-FirstCall/ -- BioTrends Research Group, Inc. released two Nephrology TreatmentTrends(TM) Publications, both syndicated reports offering comprehensive insight into the management of renal anemia and bone and mineral metabolism in Chronic Kidney Disease (CKD) and Dialysis. These reports provide information from 105 clinical Nephrologists and 195 Renal Dietitians in the US -- data were collected through an online survey fielded in March 2008. Renal Dietitians are...

2007-03-07 09:00:29

By Cornes, Paul; Coiffier, Bertrand; Zambrowski, Jean-Jacques Key words: Anemia - Blood transfusion - Cost effectiveness - Epoetin - Pharmacoeconomics ABSTRACT Background: Healthcare organizations must evaluate the cost effectiveness of the alternative therapies that are available to treat anemia and improve quality of life (QoL) of patients with cancer, that is, erythropoietic protein therapy and blood transfusion. Methods: Pharmacoeconomic studies that evaluated the cost of not...